Clinical Trials Logo

Drug Therapy clinical trials

View clinical trials related to Drug Therapy.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06223568 Not yet recruiting - Clinical trials for Squamous Cell Carcinoma of the Head and Neck

Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer

Start date: May 19, 2024
Phase: Phase 2
Study type: Interventional

Background: Throat cancer is a common tumor that can occur in people infected with the human papilloma virus (HPV). Most people with this cancer survive more than 5 years with standard chemotherapy drugs plus radiation. But radiation can cause serious adverse effects. Researchers believe that adding a vaccine (PRGN-2009) to this drug therapy may improve survival without the need for radiation. Objective: To test a study vaccine combined with standard chemotherapy in patients with HPV-associated throat cancers. Eligibility: People aged 18 years and older with newly diagnosed throat cancer associated with HPV. Design: Participants will be screened. They will have a physical exam and blood tests. They will have imaging scans and tests of their heart function and hearing. They will provide a sample of tissue from their tumor. A recent sample may be used; if none is available, a new sample will be taken. All participants will get two common drugs for treating cancer. These drugs are given through a tube attached to a needle inserted into a vein in the arm. Participants will receive these drugs on the first day of three 3-week cycles. Half of the participants will also get the vaccine. PRGN-2009 is injected under the skin in the arm. They will get these shots 4 times: 7 days before the start of the first cycle and on the 11th day of each cycle. Participants will have standard surgery to remove their tumors 3 to 6 weeks after completing the study treatment. They will have follow-up visits 3, 6, 12, and 24 months after their surgery.

NCT ID: NCT05246722 Not yet recruiting - Clinical trials for Coronary Heart Disease

Registry Study of Pharmacotherapy and Clinical Outcomes in Elderly Patients With Coronary Heart Disease (PHARM-ageing)

Start date: February 2022
Phase:
Study type: Observational [Patient Registry]

A registry study on drug therapy and clinical outcomes in elderly patients with coronary heart disease

NCT ID: NCT04184583 Not yet recruiting - Clinical trials for Acute Coronary Syndrome

Registry Study on Drug Therapy and Clinical Outcomes in Patients With Acute Coronary Syndrome

Start date: December 2019
Phase:
Study type: Observational [Patient Registry]

Registry Study on Drug Therapy and Clinical Outcomes in Patients With Acute Coronary Syndrome

NCT ID: NCT01131429 Not yet recruiting - Clinical trials for Carcinoma, Non-Small Cell Lung

A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations

Start date: June 2010
Phase: Phase 2
Study type: Interventional

Objective: the objective of this study in china is to clarify, whether the overall survival is different between previously untreated stage IIIB/IV lung adenocarcinoma with EGFR mutations receiving first-line erlotinib plus second-line docetaxel/cisplatin and those receiving first-line docetaxel/cisplatin plus second-line erlotinib .